Bisoprolol: Difference between revisions
Jump to navigation
Jump to search
imported>Robert Badgett No edit summary |
imported>Robert Badgett (Started history) |
||
| Line 3: | Line 3: | ||
Variation in the effects of bisoprolol may be due to adrenergic receptor genotypes.<ref name="pmid17585213">{{cite journal |author=Zaugg M, Bestmann L, Wacker J, ''et al'' |title=Adrenergic receptor genotype but not perioperative bisoprolol therapy may determine cardiovascular outcome in at-risk patients undergoing surgery with spinal block: the Swiss Beta Blocker in Spinal Anesthesia (BBSA) study: a double-blinded, placebo-controlled, multicenter trial with 1-year follow-up |journal=Anesthesiology |volume=107 |issue=1 |pages=33–44 |year=2007 |month=July |pmid=17585213 |doi=10.1097/01.anes.0000267530.62344.a4 |url=http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?an=00000542-200707000-00010 |issn=}}</ref> | Variation in the effects of bisoprolol may be due to adrenergic receptor genotypes.<ref name="pmid17585213">{{cite journal |author=Zaugg M, Bestmann L, Wacker J, ''et al'' |title=Adrenergic receptor genotype but not perioperative bisoprolol therapy may determine cardiovascular outcome in at-risk patients undergoing surgery with spinal block: the Swiss Beta Blocker in Spinal Anesthesia (BBSA) study: a double-blinded, placebo-controlled, multicenter trial with 1-year follow-up |journal=Anesthesiology |volume=107 |issue=1 |pages=33–44 |year=2007 |month=July |pmid=17585213 |doi=10.1097/01.anes.0000267530.62344.a4 |url=http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?an=00000542-200707000-00010 |issn=}}</ref> | ||
==History== | |||
Bisoprolol fumarate was approved in 1992.<ref>[http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Overview&DrugName=ZEBETA Drugs@FDA]. U S Food and Drug Administration</ref> [[Generic drug|Generic]] bisoprolol was approved in 2002.<ref>[http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=075474&DrugName=BISOPROLOL%20FUMARATE&ActiveIngred=BISOPROLOL%20FUMARATE&SponsorApplicant=MUTUAL%20PHARM&ProductMktStatus=3 Drugs@FDA]. U S Food and Drug Administration</ref> | |||
==Metabolism== | ==Metabolism== | ||
Revision as of 15:37, 18 June 2009
In medicine, bisoprolol is a "cardioselective beta-1-adrenergic blocker. It is effective in the management of hypertension and angina pectoris."[1]
Variation in the effects of bisoprolol may be due to adrenergic receptor genotypes.[2]
History
Bisoprolol fumarate was approved in 1992.[3] Generic bisoprolol was approved in 2002.[4]
Metabolism
It is not metabolized by cytochrome P-450 2D6 allele.
Dosage
For healthy adults, the starting dose is 5 mg orally per day (sometimes 2.5 mg) and the maximum dose is 10 to 20 mg orally per day.
External links
The most up-to-date information about Bisoprolol and other drugs can be found at the following sites.
- Bisoprolol - FDA approved drug information (drug label) from DailyMed (U.S. National Library of Medicine).
- Bisoprolol - Drug information for consumers from MedlinePlus (U.S. National Library of Medicine).
- Bisoprolol - Detailed information from DrugBank.
References
- ↑ Anonymous (2024), Bisoprolol (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Zaugg M, Bestmann L, Wacker J, et al (July 2007). "Adrenergic receptor genotype but not perioperative bisoprolol therapy may determine cardiovascular outcome in at-risk patients undergoing surgery with spinal block: the Swiss Beta Blocker in Spinal Anesthesia (BBSA) study: a double-blinded, placebo-controlled, multicenter trial with 1-year follow-up". Anesthesiology 107 (1): 33–44. DOI:10.1097/01.anes.0000267530.62344.a4. PMID 17585213. Research Blogging.
- ↑ Drugs@FDA. U S Food and Drug Administration
- ↑ Drugs@FDA. U S Food and Drug Administration